Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Eman Abdelhakeem, Mohamed El-Nabarawi & Rehab Shamma. (2021) Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy: in-vitro optimization and ex-vivo assessment. Drug Delivery 28:1, pages 642-654.
Read now
Read now
Suthasinee Sinawat, Watcharaporn Thongmee, Thuss Sanguansak, Wipada Laovirojjanakul, Supat Sinawat & Yosanan Yospaiboon. (2020) Oral Spironolactone versus Conservative Treatment for Non-Resolving Central Serous Chorioretinopathy in Real-Life Practice. Clinical Ophthalmology 14, pages 1725-1734.
Read now
Read now
Daniela Montorio, Adriano Carnevali, Riccardo Sacconi, Vittorio Capuano, Chiara Giuffrè, Alessandro Rabiolo, Luigi Antonio De Vitis, Lea Querques, Francesco Bandello & Giuseppe Querques. (2017) Mineralocorticoid receptor antagonists in the treatment of central serous chorioretinopathy. Expert Review of Ophthalmology 12:1, pages 21-25.
Read now
Read now
Dong Yang & Dean Eliott. (2017) Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy. Seminars in Ophthalmology 32:1, pages 36-42.
Read now
Read now
Articles from other publishers (37)
Eman Abdelhakeem, Mohamed El‐Nabarawi & Rehab Shamma. (2022) Eplerenone repurposing in management of chorioretinopathy: Mechanism, nanomedicine‐based delivery applications and future trends. British Journal of Clinical Pharmacology 88:6, pages 2665-2672.
Crossref
Crossref
Kyungmoo Lee, Alexis K. Warren, Michael D. Abràmoff, Andreas Wahle, S. Scott Whitmore, Ian C. Han, John H. Fingert, Todd E. Scheetz, Robert F. Mullins, Milan Sonka & Elliott H. Sohn. (2021) Automated segmentation of choroidal layers from 3-dimensional macular optical coherence tomography scans. Journal of Neuroscience Methods 360, pages 109267.
Crossref
Crossref
Doris Fraenkel, Shady Suffo, Achim Langenbucher, Berthold Seitz & Alaa Din Abdin. (2020) Eplerenone for treatment of chronic central serous chorioretinopathy. European Journal of Ophthalmology 31:4, pages 1885-1891.
Crossref
Crossref
Katrin Fasler, Jeanne M. Gunzinger, Daniel Barthelmes & Sandrine A. Zweifel. (2021) Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy. Frontiers in Pharmacology 12.
Crossref
Crossref
Jianan Duan, Yun Zhang & Meixia Zhang. (2021) Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis. Eye 35:4, pages 1102-1110.
Crossref
Crossref
Stefano Da Pozzo, Pierluigi Iacono, Alessandro Arrigo & Maurizio Battaglia Parodi. (2021) The Role of Imaging in Planning Treatment for Central Serous Chorioretinopathy. Pharmaceuticals 14:2, pages 105.
Crossref
Crossref
Dong Yoon Kim, Jong Young Lee, Eun Kyoung Lee & Jin Young Kim. (2020) COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. Retina 40:6, pages 1191-1199.
Crossref
Crossref
William Fusi-Rubiano, Habiba Saedon, Vijay Patel & Yit C. Yang. (2019) Oral medications for central serous chorioretinopathy: a literature review. Eye 34:5, pages 809-824.
Crossref
Crossref
Naoual Dahmana, Laura Kowalczuk, Doris Gabriel, Francine Behar-Cohen, Robert Gurny & Yogeshvar N. Kalia. (2019) Ocular Biodistribution of Spironolactone after a Single Intravitreal Injection of a Biodegradable Sustained-Release Polymer in Rats. Molecular Pharmaceutics 17:1, pages 59-69.
Crossref
Crossref
Ke-Hao Huang, Yi-Hao Chen, Lung-Chi Lee, Ming-Cheng Tai, Chi-Hsiang Chung, Jiann-Torng Chen, Chang-Min Liang, Wu-Chien Chien & Ching-Long Chen. (2019) Relationship between heart failure and central serous chorioretinopathy: A cohort study in Taiwan. Journal of the Chinese Medical Association 82:12, pages 941-947.
Crossref
Crossref
Thomas J. van Rijssen, Elon H.C. van Dijk, Suzanne Yzer, Kyoko Ohno-Matsui, Jan E.E. Keunen, Reinier O. Schlingemann, Sobha Sivaprasad, Giuseppe Querques, Susan M. Downes, Sascha Fauser, Carel B. Hoyng, Felice Cardillo Piccolino, Jay K. Chhablani, Timothy Y.Y. Lai, Andrew J. Lotery, Michael Larsen, Frank G. Holz, K. Bailey Freund, Lawrence A. Yannuzzi & Camiel J.F. Boon. (2019) Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Progress in Retinal and Eye Research 73, pages 100770.
Crossref
Crossref
Elodie Bousquet, Min Zhao, Alejandra Daruich & Francine Behar-Cohen. (2019) Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence. Experimental Eye Research 187, pages 107754.
Crossref
Crossref
Upma Awasthi, Rohini Grover, Abhishek Varshney & Chetan Videkar. (2019) Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy. American Journal of Ophthalmology 203, pages 121.
Crossref
Crossref
Pierluigi Iacono, Lisa Toto, Eliana Costanzo, Monica Varano & Maria Cristina Parravano. (2019) Pharmacotherapy of Central Serous Chorioretinopathy: A Review of the Current Treatments. Current Pharmaceutical Design 24:41, pages 4864-4873.
Crossref
Crossref
B. Cakir, H. Agostini & C. Lange. (2018) Behandlung der Chorioretinopathia centralis serosa mittels AldosteronantagonistenTreatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists. Der Ophthalmologe 116:2, pages 189-200.
Crossref
Crossref
Ji Hwan Lee, Sung Chul Lee, Hyesun Kim & Christopher Seungkyu Lee. (2019) COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. Retina 39:1, pages 127-133.
Crossref
Crossref
Irini Chatziralli, Aikaterini Vlachodimitropoulou, Chrysoula Daoula, Christina Vrettou, Eleni Galani, George Theodossiadis & Panagiotis Theodossiadis. (2018) Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature. International Journal of Retina and Vitreous 4:1.
Crossref
Crossref
Marion Geoffroy, Mickael Afriat, Marion Fauconier, Jean-Paul Eschard & Jean-Hugues Salmon. (2018) Effet indésirable de la corticothérapie : la choriorétinite séreuse centrale. Revue du Rhumatisme 85:5, pages 509-510.
Crossref
Crossref
Naoual Dahmana, Doris Gabriel, Robert Gurny & Yogeshvar N. Kalia. (2018) Development and validation of a fast and sensitive UHPLC-ESI-MS method for the simultaneous quantification of spironolactone and its metabolites in ocular tissues. Biomedical Chromatography 32:10, pages e4287.
Crossref
Crossref
Xinghong Sun, Yuanlu Shuai, Wangyi Fang, Jia Li, Weizhong Ge, Songtao Yuan & Qinghuai Liu. (2018) Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. British Journal of Ophthalmology 102:8, pages 1060-1065.
Crossref
Crossref
Ilaria Zucchiatti, Riccardo Sacconi, Maria Cristina Parravano, Eliana Costanzo, Lea Querques, Daniela Montorio, Francesco Bandello & Giuseppe Querques. (2018) Eplerenone Versus Observation in the Treatment of Acute Central Serous Chorioretinopathy: A Retrospective Controlled Study. Ophthalmology and Therapy 7:1, pages 109-118.
Crossref
Crossref
Ehsan Rahimy, John D. PitcherJason HsuMurtaza K. AdamAbtin ShahlaeeWasim A. SamaraJames F. VanderRichard S. KaiserAllen ChiangMarc J. SpirnMitchell S. Fineman. (2018) A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). Retina 38:5, pages 962-969.
Crossref
Crossref
R Sacconi, G Baldin, A Carnevali, L Querques, A Rabiolo, G Marchini, F Bandello & G Querques. (2018) Response of central serous chorioretinopathy evaluated by multimodal retinal imaging. Eye 32:4, pages 734-742.
Crossref
Crossref
Nisarg P. Joshi, Murtaza K. Adam, Wasim A. Samara, Abtin Shahlaee, Ehsan Rahimy, Christopher M. Aderman, Jason Hsu, Mitchell S. Fineman & Sunir J. Garg. (2017) Optical Density of Subretinal Fluid as a Predictive Biomarker for Eyes With Chronic Central Serous Retinopathy Treated With Eplerenone. Journal of VitreoRetinal Diseases 2:1, pages 6-11.
Crossref
Crossref
Marion Geoffroy, Mickael Afriat, Marion Fauconier, Jean Paul Eschard & Jean Hugues Salmon. (2018) Adverse effect of corticosteroid therapy: Central serous chorioretinopathy. Joint Bone Spine 85:1, pages 127-128.
Crossref
Crossref
Roy Schwartz, Zohar Habot-Wilner, Michael R. Martinez, Amir Nutman, Dafna Goldenberg, Shai Cohen, Shiri Shulman, Hanan Guzner-Gur, Anat Loewenstein & Michaella Goldstein. (2017) Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmologica 95:7, pages e610-e618.
Crossref
Crossref
P. Rocha Cabrera, L. Cordovés Dorta, D. Ángel Pereira, J.A. Abreu Reyes, M.J. Losada Castillo, J. Lorenzo Morales & M.Á. Serrano García. (2017) Dome shaped macula associated with myopic retinochoroidosis. Use of spironolactone. Archivos de la Sociedad Española de Oftalmología (English Edition) 92:10, pages 499-506.
Crossref
Crossref
P. Rocha Cabrera, L. Cordovés Dorta, D. Ángel Pereira, J.A. Abreu Reyes, M.J. Losada Castillo, J. Lorenzo Morales & M.Á. Serrano García. (2017) Mácula en cúpula asociada a la retinocoroidosis miópica. Utilidad de la espironolactona. Archivos de la Sociedad Española de Oftalmología 92:10, pages 499-506.
Crossref
Crossref
Anne RübsamClaudia E. ThiemeJuliane SchlombergSibylle WinterhalterBert MüllerAntonia M. JoussenNicole Stübiger. (2017) Therapy Rationale for Mineralocorticoid-Receptor Antagonists, Acetazolamide and a Switch of Therapy in Nonresponders in Central Serous Chorioretinopathy. Journal of Ocular Pharmacology and Therapeutics 33:3, pages 141-148.
Crossref
Crossref
D. Ángel-Pereira, P. Rocha-Cabrera, L. Cordovés-Dorta, M.J. Losada Castillo, A. Blasco Alberto & J.A. Abreu Reyes. (2016) Spironolactone, a therapeutic alternative in the treatment of diffuse retinal pigment epitheliopathy. Archivos de la Sociedad Española de Oftalmología (English Edition) 91:12, pages 599-603.
Crossref
Crossref
D. Ángel-Pereira, P. Rocha-Cabrera, L. Cordovés-Dorta, M.J. Losada Castillo, A. Blasco Alberto & J.A. Abreu Reyes. (2016) Espironolactona, alternativa terapéutica en el tratamiento de la epiteliopatía difusa crónica. Archivos de la Sociedad Española de Oftalmología 91:12, pages 599-603.
Crossref
Crossref
Bertan Cakir, Franziska Fischer, Christoph Ehlken, Anima Bühler, Andreas Stahl, Günther Schlunck, Daniel Böhringer, Hansjürgen Agostini & Clemens Lange. (2016) Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 254:11, pages 2151-2157.
Crossref
Crossref
Elon H. C. van Dijk, Michiel F. Nijhoff, Eiko K. de Jong, Onno C. Meijer, Aiko P. J. de Vries & Camiel J. F. Boon. (2016) Central serous chorioretinopathy in primary hyperaldosteronism. Graefe's Archive for Clinical and Experimental Ophthalmology 254:10, pages 2033-2042.
Crossref
Crossref
Christoph Leisser, Nino Hirnschall, Christoph Hackl, Pia Plasenzotti & Oliver Findl. (2015) Eplerenone in Patients with Chronic Recurring Central Serous Chorioretinopathy. European Journal of Ophthalmology 26:5, pages 479-484.
Crossref
Crossref
Seoung Hyun An & Yoon Hyung Kwon. (2015) Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 254:8, pages 1489-1496.
Crossref
Crossref
Francine Behar-Cohen & Min Zhao. (2016) Corticosteroids and the retina. Current Opinion in Neurology 29:1, pages 49-54.
Crossref
Crossref
Kapil G. Kapoor & Alan L. Wagner. (2016) Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy: A Comparative Analysis. Ophthalmic Research 56:1, pages 17-22.
Crossref
Crossref